Bridging the treatment gap in infant medulloblastoma: molecularly informed outcomes of a globally feasible regimen.

ABSTRACT:

Background

Infant medulloblastoma represents an enormous challenge in neuro-oncology, due to their simultaneous high-risk of recurrence and high risk of severe neurodevelopmental sequelae with craniospinal irradiation. Currently infant medulloblastoma are treated with intensified protocols, either comprising intraventricular methotrexate or autologous transplant, both of which carry significant morbidity and are not feasible in the majority of the world. We sought to evaluate the molecular predictors of outcome in a cohort of infants homogeneously treated with induction chemotherapy, focal radiation and maintenance chemotherapy.

Methods

In a retrospective analysis, 29 young children treated with a craniospinal irradiation sparing strategy from Hospital Garrahan in Buenos Air

SUBMITTER: Baroni LV 

PROVIDER: S-EPMC7746938 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature